Hepatitis C virus re-treatment in the era of direct-acting antivirals: projections in the USA.

Jagpreet ChhatwalQ ChenT AyerE D BetheaF KanwalK V KowdleyX WangM S RobertsS C Gordon

Published in: Alimentary pharmacology & therapeutics (2018)

Even in the era of highly effective DAAs, a significant number of patients will fail to achieve SVR and will require re-treatment options. Timely and effective re-treatment is essential to prevent the long-term sequelae of HCV.

Keyphrases

hepatitis c virus
end stage renal disease
chronic kidney disease
ejection fraction
prognostic factors
hiv infected
antiretroviral therapy